专题：Urinary and Genital Oncology Studies

This cluster of papers focuses on the clinical and pathological aspects of urachal carcinoma, including its diagnosis, management, and molecular characteristics. It also covers related topics such as primary urethral carcinoma, nephrogenic adenoma, bladder diverticulum, and immunohistochemical markers for differential diagnosis.
最新文献
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer

article Full Text OpenAlex

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

article Full Text OpenAlex

ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)

article Full Text OpenAlex

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

article Full Text OpenAlex

PD‐L1 and nectin‐4 expression and genomic characterization of bladder cancer with divergent differentiation

article Full Text OpenAlex

Vaginal leiomyoma in a perimenopausal woman: A rare case report and review of the literature

article Full Text OpenAlex

Short-term effects of bowel function on global health quality of life after radical cystectomy

article Full Text OpenAlex

Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO).

article Full Text OpenAlex

Handling and pathology reporting guidelines for bladder epithelial neoplasms – recommendations from the Brazilian Society of Pathology / Brazilian Society of Urology / Brazilian Society of Clinical Oncology

article Full Text OpenAlex

Urachal mixed adenocarcinoma and small cell neuroendocrine carcinoma with widespread metastasis and resistance to chemotherapy: a case report

article Full Text OpenAlex

近5年高被引文献
European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)

review Full Text OpenAlex 1420 FWCI284.01243988

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

article Full Text OpenAlex 1021 FWCI190.95196271

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

article Full Text OpenAlex 912 FWCI183.06979115

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

article Full Text OpenAlex 665 FWCI829.09371766

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

article Full Text OpenAlex 613 FWCI134.50544377

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines

review Full Text OpenAlex 507 FWCI227.18475672

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

article Full Text OpenAlex 490 FWCI97.63722195

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

article Full Text OpenAlex 478 FWCI92.04342277

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

article Full Text OpenAlex 458 FWCI84.924042

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

review Full Text OpenAlex 425 FWCI216.60630907